Skip to content
Screener

Capricor Therapeutics CAPR Business Segments — Other General And Administrative Expense

Similar metrics at other companies

ArriVent BioPharma, Inc. logo
AVBPSingle Reportable — Other General And Administrative Expense
$2.31M+7.4%
Citi Trends logo
CTRNSingle Reportable — Other General And Administrative Expense
$26.41M+9.0%
Scholar Rock logo
SRRKSingle Reportable — Other General And Administrative Expense
$16.6M+11.0%
XOM
XOMASingle Reportable — Other General And Administrative Expense
$11.04M+55.7%
EVgo, Inc. logo
EVGOSingle Reportable — Other General And Administrative Expense
$12.14M+20.3%
Theravance Biopharma logo
TBPHSingle Reportable — Other General And Administrative Expense
$7.96M+9.7%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$242.07M-31.6%
Enterprise value$151.43M-54.3%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherGeneralAndAdministrativeExpense.

The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060382
Total revenueThree months ended March 31, 2026 / —Three months ended March 31, 2025 / —
Total research and development expense27,376,91218,915,572
General and administrative expense:
Compensation and benefits2,234,9481,500,843
Other G&A segment expenses (2)4,115,7641,375,233
Total general and administrative expense, excluding non-cash expense6,350,7122,876,076
Stock-based compensation expense2,791,8743,000,814
Depreciation and amortization253,355190,486
Total general and administrative expense9,395,9416,067,376

Item 1. Financial Statements.

FAQ

What is Capricor Therapeutics's business segments — other general and administrative expense?
Capricor Therapeutics (CAPR) reported business segments — other general and administrative expense of $4.12M in Q1 2026.
How has Capricor Therapeutics's business segments — other general and administrative expense changed year-over-year?
Capricor Therapeutics's business segments — other general and administrative expense increased by 199.3% year-over-year, from $1.38M to $4.12M.
What does business segments — other general and administrative expense mean?
This metric encompasses miscellaneous operating costs within the general and administrative category that are not classified as labor, share-based compensation, or depreciation. It typically includes professional fees, insurance, office overhead, and other corporate support costs. Tracking this provides insight into the efficiency of the company's back-office and administrative spending.

Ask your AI about Capricor Therapeutics's business segments — other general and administrative expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude